Loading

Search

https://lifescienceleader.com

Life Science Leader - Home Page
Life Science Leader - thought leadership articles and discussions about the current life science industry
Life Science Leader - Home Page Get more Life Science Leader insight with our FREE newsletter. sign me up Log In or Subscribe Home Magazine Past Issues Digital Edition Articles Executive Interviews Companies To Watch Where Are They Now Industry Leader CEO Corner Ask The Board Key Topics Clinical Trials Finance-Funding Outsourcing Regulatory Research & Development Business of Biotech Podcast Why Life Sciences Demand Venture Formation Over Venture Capital The life sciences industry needs venture formation, not traditional VC, to turn academic breakthroughs into successful startups, writes William Garner, M.D. When AI Changes A Deal: Rethinking Risk, Milestones, And Timing In Life Sciences M&A Bridging The Gap: The Contract-To-Ledger Divide In Life Sciences Rebuilding the Innovation Engine: How We Got Here And What Comes Next Psychedelics EO May De-Risk Innovation, But Data Is Still King Why Breakthrough Research Sits On The Shelf, And What To Do About It Godzilla Vs. The Life Sciences Supply Chain BIO 2026: China, AI, And FDA Beyond The Fine Print: OPDP's 2026 DTC Letters Redefine Net Impression The Next Chapter Of Obesity And Type 2 Diabetes Care: ADA 2026 Signals A More Personalized Future Understanding FDA's Plausible Mechanism Framework For Genetic Medicines More Articles COMPANIES TO WATCH Companies To Watch: Vivani Medical Vivani Medical is developing GLP-1 subdermal implants that aim to provide a consistent therapeutic dose for six months, and possibly one full year. The company's lead program is an exenatide implant. Companies To Watch: Imunon Imunon aims to shake up the standard of care in the frontline treatment of advanced ovarian cancer. Companies To Watch: Senti Bio Senti Bio aims to improve cancer therapeutics with customizable gene circuits, or multi-gene constructs capable of identifying cancer targets on both healthy and diseased cells. Companies To Watch: Terns Pharmaceuticals Terns Pharmaceuticals aims to improve upon currently marketed therapies in CML and obesity, using internally discovered small molecules. More Companies To Watch WHERE ARE THEY NOW Where Are They Now? Life Science Cares Life Science Cares, an industry philanthropic organization, turns 10 in April. Now in five cities and Switzerland, the organization remains focused on fighting poverty. Where Are They Now? Tarsus Pharmaceuticals Tarsus Pharmaceuticals is making a splash with Xdemvy, an eye drop that kills the demodex mites that cause inflammation and irritation in the eyelid. A new consumer DTC campaign, potential global approvals, and a new indication in the clinic could turn Xdemvy into a blockbuster drug. Where Are They Now? Teva Pharmaceuticals Teva Pharmaceuticals "pivot to growth" strategy under CEO Richard Francis aims to use a combination of biosimilars, generics, and branded drugs to set the company back on track, or back to the future. More Where Are They Now NEWSLETTER ARCHIVE 07.31.26 -- Rebuilding The Innovation Engine: How We Got Here And What Comes Next 07.29.26 -- Psychedelics EO May De-Risk Innovation, But Data Is Still King 07.27.26 -- Why Breakthrough Research Sits On The Shelf, And What To Do About It 07.26.26 -- Rebuilding The U.S. Biotech Innovation Engine 07.24.26 -- BoB@BIO: Biotech In The Balance With Ovid Therapeutics' Dr. Jeremy Levin More Newsletters Newsletter Signup Get the latest articles from Life Science Leader delivered to your inbox. I agree to the Terms. I agree to the Privacy Policy. SIGN ME UP BIO 2026: China, AI, And FDA Where Are They Now? Life Science Cares On The Road: The Business Of Biotech In San Francisco For JPM2026 Galien Forum: CEOs Talk FDA, China, Funding Sources Makary Talks Faster Drug Reviews, 'Continuous Trials,' DTC Ads More From The Editor SPOTLIGHT Day One Bio Aims To Shorten The Time Gap On Cancer Treatments For Kids Day One Bio aims to bring new cancer therapies to pediatric patients faster amid evolving financial incentives, such as the recent sunset of the FDA's rare pediatric disease Priority Review Voucher program. More Spotlight Articles LIFE SCIENCE LEADER CONTENT COLLECTIONS Adapting With Automation: A Guide For The Modern Lab Vaccine Maker's Toolkit: Strategies For Manufacturing And Supply Management Scaling Cell and Gene Therapies Your Supply Chain On Inflation: An Outsourcing Analysis Improving Diversity In Clinical Trials More Content Collections Partner With Us Our Partners Request More Information Subscribe Newsletter Subscription Life Science Connect Advancing RNA Bioprocess Online Biosimilar Development Cell & Gene Clinical Leader Clinical Supply Leader Clinical Tech Leader Drug Discovery Drug Delivery Leader Laboratory Network Med Device Online Outsourced Pharma Pharmaceutical Online Editorial Current Issue Past Issues Digital Edition Article Reprints Editorial Advisory Board Editorial Submission Guidelines Events CMO Leadership Awards CDMO Live Americas CDMO Live Europe External Manufacturing Leaders Learn More About Us Contact Us Who We Are Work For Us Copyright © 1996-2026 VertMarkets, Inc. All Rights Reserved. Terms of Use. Privacy Statement. Subscriber Request Form. Don't sell my information ×
1785863164
https://lifescienceleader.com

Edit your site?

What are you doing?

0.0060198307037354


Webdirectory
Webdirectory

Webdirectory
Life Science Leader - thought leadership articles and discussions about the current life science industry
Webdirectory